AstraZeneca (AZN) Announces Strategic Research Collaboration with CSPC Pharmaceuticals

AstraZeneca PLC (NASDAQ:AZN) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 13, AstraZeneca PLC (NASDAQ:AZN) announced that it had entered into a strategic research collaboration with CSPC Pharmaceuticals Group Limited, based in Shijiazhuang City. The research collaboration aims to discover and develop novel oral candidates with the hopes of treating diseases across multiple indications.

Under the agreement, the two companies will discover and develop pre-clinical candidates for various targets related to the treatment of diseases across chronic indications. This includes a pre-clinical small molecule oral therapy for immunological diseases.

CSPC would conduct the research in Shijiazhuang City, utilizing its AI-driven, dual-engine efficient drug discovery platform. The collaboration is expected to expand AstraZeneca PLC’s (NASDAQ:AZN) presence in China following the announcement of a $2.5 billion investment to develop a new global strategic R&D center in Beijing earlier in the year.

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians. AstraZeneca PLC (NASDAQ:AZN) distributes its products and services through local representative offices and distributors.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.